Natera, Inc. - Common Stock (NTRA)

211.85
-0.88 (-0.41%)
NASDAQ· Last Trade: Jun 3rd, 6:08 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia)fool.com
The famous hedge fund manager seems to have found a hidden gem outside of the market's most popular stock picks.
Via The Motley Fool · June 3, 2026
NWI Management Dumps 42,700 MercadoLibre Shares Worth $82.4 Millionfool.com
MercadoLibre delivers e-commerce and fintech solutions across Latin America, leveraging an integrated digital ecosystem for regional growth.
Via The Motley Fool · May 30, 2026
1 Mid-Cap Stock with Exciting Potential and 2 That Underwhelm
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
Via StockStory · May 19, 2026
5 Must-Read Analyst Questions From Natera’s Q1 Earnings Call
Natera’s first quarter was marked by robust top-line growth and higher-than-expected sales volumes, but the market responded negatively due to a wider-than-a...
Via StockStory · May 14, 2026
Natera (NTRA) Q1 Revenue Beat Overshadowed by EPS Miss and Operating Losseschartmill.com
Via Chartmill · May 7, 2026
Why Natera (NTRA) Shares Are Plunging Today
What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). fell 12.2% in the afternoon session after the company reported mixed first-quarter 202...
Via StockStory · May 8, 2026
Natera Q1 Earnings Call Highlightsmarketbeat.com
Natera (NASDAQ:NTRA) reported first-quarter 2026 revenue of $697 million, up 39% year over year, as the company delivered more than 1 million total units in a single quarter for the first time. Chief Executive Officer Steve Chapman said strong performance in women’s health and another record quarter
Via MarketBeat · May 8, 2026
NTRA Q1 Deep Dive: Robust Volume Growth and Product Expansion Shape Outlook
Genetic testing company Natera (NASDAQ:NTRA). reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 38.8% year on year to $696....
Via StockStory · May 8, 2026
Natera NTRA Q1 2026 Earnings Call Transcriptfool.com
Natera NTRA Q1 2026 Earnings Call Transcript
Via The Motley Fool · May 7, 2026
Natera’s (NASDAQ:NTRA) Q1 CY2026 Sales Top Estimates
Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2026, with sales up 38.8% year on year to $696.6 million. Its GA...
Via StockStory · May 7, 2026
What To Expect From Natera’s (NTRA) Q4 Earnings
Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results this Thursday afternoon. Here’s what to expect. Natera beat analysts’ reven...
Via StockStory · May 5, 2026
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via StockStory · April 20, 2026
3 Reasons We’re Fans of Natera (NTRA)
Natera has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6%. The stock now trades at $208.20, marking a 10.5% gain....
Via StockStory · April 20, 2026
Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener...
Via StockStory · April 17, 2026
1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Via StockStory · April 15, 2026
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 We Find Risky
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Via StockStory · April 9, 2026
3 Reasons NTRA Has Explosive Upside Potential
Even during a down period for the markets, Natera has gone against the grain, climbing to $211.23. Its shares have yielded a 22.1% return over the last six m...
Via StockStory · April 9, 2026
Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Via StockStory · March 27, 2026
Abbott Laboratories Finalizes $21 Billion Acquisition of Exact Sciences, Redefining the Future of Cancer Diagnostics
CHICAGO — In a move that fundamentally reshapes the global diagnostics landscape, Abbott Laboratories (NYSE: ABT) officially completed its $21 billion acquisition of Exact Sciences (NASDAQ: EXAS) today, March 23, 2026. The closing of the deal marks the end of a high-stakes transition period and the beginning of a new era
Via MarketMinute · March 23, 2026
1 Unprofitable Stock to Own for Decades and 2 Facing Headwinds
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...
Via StockStory · March 20, 2026
1 Cash-Heavy Stock to Target This Week and 2 We Question
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
Via StockStory · March 19, 2026
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ...
Via StockStory · March 16, 2026
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investmentfool.com
Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders.
Via The Motley Fool · March 16, 2026
This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stockfool.com
Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide.
Via The Motley Fool · March 16, 2026
3 Growth Stocks to Add to Your Roster
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...
Via StockStory · March 16, 2026